Tourette's device tested by Lewis Capaldi
bbc.com

Tourette's device tested by Lewis Capaldi

Archived — this story has rotated out of today’s deck. It is kept here in full.

The gist

A wrist device from University of Nottingham researchers, tested by singer Lewis Capaldi, cut tic frequency by 25% on average in a 121-person UK trial.
The medical version still lacks regulatory approval, so NHS access is not yet settled.

Background

The device, called Neupulse, was developed by researchers at the University of Nottingham with its spin-out company Neurotherapeutics Ltd, which secured £1m in additional funding to commercialise it. It delivers electrical pulses to the median nerve at the wrist, which trials have shown can change activity in the brain areas involved in movement control and reduce the frequency and intensity of tics. Scottish singer Lewis Capaldi, who has Tourette's, tested it before a gig in Nottingham. It comes in two versions: Neupulse-C, sold as a consumer wellness device, and Neupulse-M, intended as a medical treatment but not yet regulatory approved.

How it unfolded

  1. 2023A clinical trial of 121 people in the UK found an average 25% reduction in tic frequency while using a prototype of the device.
  2. 2023Singer Lewis Capaldi, who has Tourette's, tested the device before a gig in Nottingham.
  3. Nov 12, 2026BBC reported that the wrist device has been described as "life-changing" by people with the condition.

Key terms

Tourette's
A neurological disorder beginning in childhood, marked by multiple motor tics and at least one vocal tic.
NHS
The collective name for the four publicly funded healthcare systems of the United Kingdom.
NICE
A UK government body that assesses health technologies and issues guidance on their use in the NHS.

Source: Wikipedia

Who’s saying what

Public
Katie, 15, from Hertfordshire, an early user of Neupulse, said trying it was "absolutely life-changing" and "like the best day of my life", with an "instant" effect.
Expert
Prof Stephen Jackson, who leads the research, said seeing the impact on users was "a dream come true" and that the team is working to get regulatory approval, hoping it will be available on the NHS "in the next year or so".
Caution
Tourettes Action said Neupulse-M has not yet received regulatory approval, and that NICE called the technology "promising" but requested further evidence of long-term benefits before recommending NHS adoption.

Still unverified

Neupulse-M is still going through the regulatory approval process; NHS use would only be considered if approval is obtained, and NICE has asked for further evidence of long-term benefits before making recommendations.

Sources

See today’s stories in the app Gistline — free on the App Store